{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:13:23Z","timestamp":1790010803574,"version":"4.0.1"},"reference-count":118,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagonomas are a rare hormone-producing pancreatic neuroendocrine tumor (panNET), with an estimated incidence of 1 to 2 cases per million persons. They typically present at diagnosis as large, metastatic panNET and are characterized clinically by diabetes mellitus, weight loss, thromboembolic complications and necrolytic migratory erythema. The diagnosis of glucagonoma syndrome requires the presence of both elevated fasting plasma glucagon levels and glucagonoma symptoms. Staging relies on cross-sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI), complemented by somatostatin receptor positron emission tomography (PET) imaging. Initial management of glucagonoma includes supportive therapy with supplementation of amino acids, essential fatty acids, zinc, and other micronutrients as well as glycemic control and anticoagulation. Surgical resection is the only curative treatment. For unresectable or metastatic disease, palliative management parallels that of nonfunctioning panNET and includes somatostatin analogues, targeted therapies, peptide receptor radionuclide therapy with radiolabeled somatostatin analogues, and cytotoxic chemotherapy. Prognosis depends on tumor stage and grade, with reported 10-year survival rates approaching 100% for localized disease and approximately 50% for metastatic glucagonoma. A rare hereditary cause of hyperglucagonemia due to glucagon receptor mutations is glucagon cell hyperplasia and neoplasia, also termed Mahvash disease. These patients develop alpha cell hyperplasia and panNET but lack the classical glucagonoma symptoms. In conclusion, fasting glucagon levels should be measured in patients with typical features such as necrolytic migratory erythema, an advanced panNET associated with cachexia and new-onset or worsening diabetes mellitus or diffuse alpha cell hyperplasia.<\/jats:p>","DOI":"10.1210\/clinem\/dgag371","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:52:48Z","timestamp":1788616368000},"source":"Crossref","is-referenced-by-count":0,"title":["Approach to the patient with primary hyperglucagonemia"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3169-2599","authenticated-orcid":false,"given":"Jelka","family":"Kuiper","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center and Erasmus MC Cancer Institute , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-5165","authenticated-orcid":false,"given":"Wouter W","family":"de Herder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center and Erasmus MC Cancer Institute , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Feelders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center and Erasmus MC Cancer Institute , 3015 GD Rotterdam ,","place":["The Netherlands"]},{"name":"Holman Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University Langone Medical Center , New York, NY 10016 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-6209","authenticated-orcid":false,"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center and Erasmus MC Cancer Institute , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"6","key":"2026092112474581200_dgag371-B1","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0087","article-title":"Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations","volume":"32","author":"Kuiper","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2026092112474581200_dgag371-B2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/BF00274797","article-title":"Pancreatic and intestinal processing of proglucagon in man","volume":"30","author":"Orskov","year":"1987","journal-title":"Diabetologia"},{"issue":"2","key":"2026092112474581200_dgag371-B3","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0224","article-title":"Brief overview: glucagon history and physiology","volume":"258","author":"Robertson","year":"2023","journal-title":"J Endocrinol"},{"key":"2026092112474581200_dgag371-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170942","article-title":"Glucagon 100 years. Important, but still enigmatic","volume":"161","author":"Holst","year":"2023","journal-title":"Peptides"},{"issue":"1","key":"2026092112474581200_dgag371-B5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026092112474581200_dgag371-B6","first-page":"309","volume-title":"WHO Classification of Tumours. Endocrine and Neuroendocrine Tumours","author":"La Rosa","year":"2023"},{"issue":"13","key":"2026092112474581200_dgag371-B7","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3390\/ijms20133314","article-title":"Glucagon receptor signaling and glucagon resistance","volume":"20","author":"Janah","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026092112474581200_dgag371-B8","first-page":"45","article-title":"Metabolic effects of glucagon in humans","volume":"15","author":"Adeva-Andany","year":"2019","journal-title":"J Clin Transl Endocrinol"},{"issue":"7","key":"2026092112474581200_dgag371-B9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41574-025-01100-4","article-title":"Islet hormones at the intersection of glucose and amino acid metabolism","volume":"21","author":"White","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2026092112474581200_dgag371-B10","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/en.2016-1748","article-title":"Insulin and glucagon: partners for life","volume":"158","author":"Holst","year":"2017","journal-title":"Endocrinology"},{"issue":"1","key":"2026092112474581200_dgag371-B11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0021-9258(18)85474-6","article-title":"Aqueous extracts of pancreas. III. Some precipitation reactions of insulin","volume":"58","author":"Kimball","year":"1923","journal-title":"J Biol Chem"},{"issue":"8","key":"2026092112474581200_dgag371-B12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJM197108192850806","article-title":"Glucagon physiology and pathophysiology","volume":"285","author":"Unger","year":"1971","journal-title":"N Engl J Med"},{"issue":"2","key":"2026092112474581200_dgag371-B13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"M\u00fcller","year":"2017","journal-title":"Physiol Rev"},{"issue":"1","key":"2026092112474581200_dgag371-B14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beem.2015.10.004","article-title":"A short history of neuroendocrine tumours and their peptide hormones","volume":"30","author":"de Herder","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"25","key":"2026092112474581200_dgag371-B15","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1056\/NEJM198106183042504","article-title":"Glucagon and the A cell: physiology and pathophysiology (first two parts)","volume":"304","author":"Unger","year":"1981","journal-title":"N Engl J Med"},{"issue":"3","key":"2026092112474581200_dgag371-B16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3181\/00379727-102-25338","article-title":"Glucagon antibodies and their use for immunoassay for glucagon","volume":"102","author":"Unger","year":"1959","journal-title":"Proc Soc Exp Biol Med"},{"issue":"7","key":"2026092112474581200_dgag371-B17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1172\/JCI104357","article-title":"Glucagon antibodies and an immunoassay for glucagon","volume":"40","author":"Unger","year":"1961","journal-title":"J Clin Invest"},{"key":"2026092112474581200_dgag371-B18","first-page":"987","article-title":"Glucagon-producing tumors of the islets of Langerhans","volume":"42","author":"Unger","year":"1963","journal-title":"J Clin Invest"},{"issue":"25","key":"2026092112474581200_dgag371-B19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJM196606232742503","article-title":"A glucagon-secreting alpha-cell carcinoma of the pancreas","volume":"274","author":"McGavran","year":"1966","journal-title":"N Engl J Med"},{"issue":"6","key":"2026092112474581200_dgag371-B20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archderm.1942.01500120037004","article-title":"Cutaneous manifestations of internal malignant tumours","volume":"45","author":"Becker","year":"1942","journal-title":"Arch Dermatol Syphilol"},{"issue":"5","key":"2026092112474581200_dgag371-B21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.1967.tb11492.x","article-title":"A cutaneous syndrome associated with islet-cell carcinoma of the pancreas","volume":"79","author":"Church","year":"1967","journal-title":"Br J Dermatol"},{"issue":"12","key":"2026092112474581200_dgag371-B22","first-page":"1197","article-title":"Necrolytic migratory erythema with pancreatic carcinoma","volume":"64","author":"Wilkinson","year":"1971","journal-title":"Proc R Soc Med"},{"issue":"7871","key":"2026092112474581200_dgag371-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(74)91343-9","article-title":"A glucagonoma syndrome","volume":"2","author":"Mallinson","year":"1974","journal-title":"Lancet"},{"issue":"3","key":"2026092112474581200_dgag371-B24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.1974.tb06406.x","article-title":"A dermatosis specifically associated with a tumour of pancreatic alpha cells","volume":"90","author":"Sweet","year":"1974","journal-title":"Br J Dermatol"},{"issue":"5","key":"2026092112474581200_dgag371-B25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.pas.0000194044.01104.25","article-title":"Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome","volume":"30","author":"Anlauf","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2026092112474581200_dgag371-B26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MPA.0b013e31815ceb23","article-title":"Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature","volume":"36","author":"Yu","year":"2008","journal-title":"Pancreas"},{"issue":"3","key":"2026092112474581200_dgag371-B27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s005340050052","article-title":"Glucagonomas\/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases","volume":"5","author":"Soga","year":"1998","journal-title":"J Hepatobiliary Pancreat Surg"},{"issue":"4","key":"2026092112474581200_dgag371-B28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cen.15300","article-title":"Glucagonoma and glucagonoma syndrome: an updated review","volume":"103","author":"Anelli","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026092112474581200_dgag371-B29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/ejendo\/lvad157","article-title":"Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network","volume":"189","author":"Perrier","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026092112474581200_dgag371-B30","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/DAD.0000000000001219","article-title":"Glucagonoma-associated necrolytic migratory erythema: the broad spectrum of the clinical and histopathological findings and clues to the diagnosis","volume":"41","author":"Toberer","year":"2019","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"2026092112474581200_dgag371-B31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1210\/endrev\/bnz004","article-title":"Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms","volume":"41","author":"Hofland","year":"2020","journal-title":"Endocr Rev"},{"issue":"7","key":"2026092112474581200_dgag371-B32","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1136\/hrt.2004.036905","article-title":"Reversible dilated cardiomyopathy associated with glucagonoma","volume":"90","author":"Chang-Chretien","year":"2004","journal-title":"Heart"},{"issue":"1","key":"2026092112474581200_dgag371-B33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.14310\/horm.2002.1557","article-title":"Reversal of dilated cardiomyopathy after glucagonoma excision","volume":"14","author":"Demir","year":"2015","journal-title":"Hormones (Athens)"},{"issue":"2","key":"2026092112474581200_dgag371-B34","article-title":"Glucagonoma-induced dilated cardiomyopathy in a young woman","volume":"1","author":"Ng","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"8","key":"2026092112474581200_dgag371-B35","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1111\/jdv.14852","article-title":"Normoglycemic glucagonoma syndrome associated with necrolytic migratory erythema","volume":"32","author":"Feldmann","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2026092112474581200_dgag371-B36","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1056\/NEJMicm1915564","article-title":"Necrolytic migratory erythema associated with a glucagonoma","volume":"383","author":"Banerjee","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"2026092112474581200_dgag371-B37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s11606-013-2490-5","article-title":"Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome","volume":"28","author":"Halvorson","year":"2013","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2026092112474581200_dgag371-B38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00005792-199603000-00002","article-title":"The glucagonoma syndrome. Clinical and pathologic features in 21 patients","volume":"75","author":"Wermers","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2026092112474581200_dgag371-B39","first-page":"4","article-title":"Etiology and pathogenesis of necrolytic migratory erythema: review of the literature","volume":"6","author":"Tierney","year":"2004","journal-title":"MedGenMed"},{"issue":"4","key":"2026092112474581200_dgag371-B40","first-page":"3389","article-title":"Glucagonoma: from skin lesions to the neuroendocrine component (review)","volume":"20","author":"Sandru","year":"2020","journal-title":"Exp Ther Med"},{"issue":"9","key":"2026092112474581200_dgag371-B41","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0020","article-title":"Emerging therapies for malignant insulinomas and glucagonomas","volume":"30","author":"Alexandraki","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2026092112474581200_dgag371-B42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bpg.2012.12.003","article-title":"Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances","volume":"26","author":"Ito","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"12","key":"2026092112474581200_dgag371-B43","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1245\/s10434-007-9566-6","article-title":"Population-based study of islet cell carcinoma","volume":"14","author":"Yao","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"2026092112474581200_dgag371-B44","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0399-8320(04)95184-6","article-title":"Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry","volume":"28","author":"L\u00e9vy-Bohbot","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"issue":"5","key":"2026092112474581200_dgag371-B45","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0245","article-title":"Genetic disorders and insulinoma\/glucagonoma","volume":"31","author":"Marini","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2026092112474581200_dgag371-B46","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"2026092112474581200_dgag371-B47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000511791","article-title":"Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome - an international consensus statement","volume":"111","author":"Niederle","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"8","key":"2026092112474581200_dgag371-B48","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-8587(25)00119-6","article-title":"Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice","volume":"13","author":"Brandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026092112474581200_dgag371-B49","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MPA.0000000000001044","article-title":"Mahvash disease: 10 years after discovery","volume":"47","author":"Yu","year":"2018","journal-title":"Pancreas"},{"issue":"8","key":"2026092112474581200_dgag371-B50","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0032","article-title":"Glucagon cell hyperplasia and neoplasia: a recently recognized endocrine receptor disease","volume":"30","author":"Sipos","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026092112474581200_dgag371-B51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MPA.0b013e31825b6acd","article-title":"Glucagon cell adenomatosis without glucagon receptor mutation","volume":"42","author":"Al-Sarireh","year":"2013","journal-title":"Pancreas"},{"issue":"5","key":"2026092112474581200_dgag371-B52","doi-asserted-by":"crossref","first-page":"E783","DOI":"10.1210\/jc.2014-4405","article-title":"Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations","volume":"100","author":"Sipos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026092112474581200_dgag371-B53","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.cmet.2017.05.011","article-title":"Interrupted glucagon signaling reveals hepatic alpha cell axis and role for L-glutamine in alpha cell proliferation","volume":"25","author":"Dean","year":"2017","journal-title":"Cell Metab"},{"issue":"2","key":"2026092112474581200_dgag371-B54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2337\/db16-0994","article-title":"Glucagon and amino acids are linked in a mutual feedback cycle: the liver-alpha-cell axis","volume":"66","author":"Holst","year":"2017","journal-title":"Diabetes"},{"issue":"6","key":"2026092112474581200_dgag371-B55","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cmet.2017.05.006","article-title":"Amino acid transporter Slc38a5 controls glucagon receptor inhibition-induced pancreatic alpha cell hyperplasia in mice","volume":"25","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"issue":"3","key":"2026092112474581200_dgag371-B56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.celrep.2015.06.034","article-title":"Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of alpha-cell mass","volume":"12","author":"Solloway","year":"2015","journal-title":"Cell Rep"},{"issue":"2","key":"2026092112474581200_dgag371-B57","doi-asserted-by":"crossref","DOI":"10.20945\/2359-4292-2026-0005","article-title":"Challenging the recessive paradigm of Mahvash disease: heterozygous phenotypes from a novel splice-site variant","volume":"70","author":"Bugallo","year":"2026","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"2026092112474581200_dgag371-B58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s13340-024-00704-x","article-title":"Advances in the clinical measurement of glucagon: from diagnosis to therapy","volume":"15","author":"Kitamura","year":"2024","journal-title":"Diabetol Int"},{"issue":"21","key":"2026092112474581200_dgag371-B59","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.3390\/ijms20215416","article-title":"Methods and guidelines for measurement of glucagon in plasma","volume":"20","author":"Holst","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026092112474581200_dgag371-B60","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJM197703102961003","article-title":"Familial hyperglucagonemia\u2013an autosomal dominant disorder","volume":"296","author":"Boden","year":"1977","journal-title":"N Engl J Med"},{"issue":"3","key":"2026092112474581200_dgag371-B61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1210\/edrv-2-3-347","article-title":"The glucagonoma syndrome: clinical features, diagnosis, and treatment","volume":"2","author":"Stacpoole","year":"1981","journal-title":"Endocr Rev"},{"issue":"3","key":"2026092112474581200_dgag371-B62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12032-007-0011-2","article-title":"Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years","volume":"24","author":"Kindmark","year":"2007","journal-title":"Med Oncol"},{"issue":"11","key":"2026092112474581200_dgag371-B63","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2967\/jnumed.124.267939","article-title":"Routine use of [(64)Cu]Cu-DOTATATE PET\/CT in a neuroendocrine tumor center: referral patterns and image results of 2,249 consecutive scans","volume":"65","author":"Carlsen","year":"2024","journal-title":"J Nucl Med"},{"issue":"8","key":"2026092112474581200_dgag371-B64","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13420","article-title":"Clinical impact of using [(18)F]AlF-NOTA-octreotide PET\/CT instead of [(68)Ga]Ga-DOTA-SSA PET\/CT: secondary endpoint analysis of a multicenter, prospective trial","volume":"36","author":"Leupe","year":"2024","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"2026092112474581200_dgag371-B65","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J Nucl Med"},{"issue":"10","key":"2026092112474581200_dgag371-B66","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jnci\/djs208","article-title":"TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study","volume":"104","author":"Rindi","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2026092112474581200_dgag371-B67","first-page":"296","volume-title":"WHO Classification of Tumours. Endocrine and Neuroendocrine Tumours","author":"Klimstra","year":"2023","edition":"5th ed."},{"issue":"3","key":"2026092112474581200_dgag371-B68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamadermatol.2015.3538","article-title":"Rapid clearance of necrolytic migratory erythema following intravenous administration of amino acids","volume":"152","author":"Thomaidou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2026092112474581200_dgag371-B69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11154-018-9443-6","article-title":"Supportive therapy in gastroenteropancreatic neuroendocrine tumors: often forgotten but important","volume":"19","author":"Jin","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"2026092112474581200_dgag371-B70","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-229115","article-title":"Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma","volume":"12","author":"Saavedra","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2026092112474581200_dgag371-B71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/qjmed\/hct027","article-title":"Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections","volume":"107","author":"Lo","year":"2014","journal-title":"QJM"},{"issue":"3","key":"2026092112474581200_dgag371-B72","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"2026092112474581200_dgag371-B73","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/RLU.0000000000003731","article-title":"Treatment of glucagonoma-related necrolytic migratory erythema with peptide receptor radionuclide therapy","volume":"46","author":"Mavi","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2026092112474581200_dgag371-B74","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026092112474581200_dgag371-B75","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7326\/0003-4819-91-2-213","article-title":"Amino acid deficiency and the skin rash associated with glucagonoma","volume":"91","author":"Norton","year":"1979","journal-title":"Ann Intern Med"},{"issue":"12","key":"2026092112474581200_dgag371-B76","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"38","key":"2026092112474581200_dgag371-B77","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017037","article-title":"Spleen-preserving distal pancreatectomy and lymphadenectomy for glucagonoma syndrome: a case report","volume":"98","author":"Cao","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"2026092112474581200_dgag371-B78","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1245\/s10434-012-2462-8","article-title":"Synchronous resection of primary and liver metastases for neuroendocrine tumors","volume":"19","author":"Gaujoux","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2026092112474581200_dgag371-B79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12328-014-0471-9","article-title":"Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide","volume":"7","author":"Kimbara","year":"2014","journal-title":"Clin J Gastroenterol"},{"issue":"7","key":"2026092112474581200_dgag371-B80","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"issue":"12","key":"2026092112474581200_dgag371-B81","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kudla","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"2026092112474581200_dgag371-B82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/OP-25-00133","article-title":"Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"22","author":"Perez","year":"2026","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"2026092112474581200_dgag371-B83","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"2026092112474581200_dgag371-B84","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2026092112474581200_dgag371-B85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study","volume":"23","author":"Caplin","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2026092112474581200_dgag371-B86","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","article-title":"Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results","volume":"157","author":"Pavel","year":"2021","journal-title":"Eur J Cancer"},{"issue":"16","key":"2026092112474581200_dgag371-B87","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026092112474581200_dgag371-B88","article-title":"Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas","volume":"5","author":"Armeni","year":"2025","journal-title":"Endocr Oncol"},{"key":"2026092112474581200_dgag371-B89","author":"Baudin"},{"key":"2026092112474581200_dgag371-B90","author":"Walter"},{"key":"2026092112474581200_dgag371-B91","doi-asserted-by":"crossref","first-page":"S941","DOI":"10.1016\/j.annonc.2025.08.2334","article-title":"1706O efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: phase III COMPETE trial","volume":"36","author":"Capdevila","year":"2025","journal-title":"Ann Oncol"},{"issue":"10551","key":"2026092112474581200_dgag371-B92","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(26)00604-5","article-title":"[(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial","volume":"408","author":"Walter","year":"2026","journal-title":"Lancet"},{"issue":"10446","key":"2026092112474581200_dgag371-B93","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"issue":"32","key":"2026092112474581200_dgag371-B94","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026092112474581200_dgag371-B95","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/MPA.0000000000000830","article-title":"Everolimus effect on gastrin and glucagon in pancreatic neuroendocrine tumors","volume":"46","author":"Pavel","year":"2017","journal-title":"Pancreas"},{"issue":"11","key":"2026092112474581200_dgag371-B96","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/annonc\/mdz219","article-title":"A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial","volume":"30","author":"Kulke","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"2026092112474581200_dgag371-B97","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2026092112474581200_dgag371-B98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-020-00784-0","article-title":"Updated efficacy and safety outcomes for patients with well-differentiated pancreatic neuroendocrine tumors treated with sunitinib","volume":"16","author":"Fazio","year":"2021","journal-title":"Target Oncol"},{"issue":"7","key":"2026092112474581200_dgag371-B99","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"2026092112474581200_dgag371-B100","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092112474581200_dgag371-B101","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0292","article-title":"Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms","volume":"32","author":"Solar Vasconcelos","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2026092112474581200_dgag371-B102","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s43018-025-00916-3","article-title":"Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis","volume":"6","author":"Cousin","year":"2025","journal-title":"Nat Cancer"},{"issue":"12","key":"2026092112474581200_dgag371-B103","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105922","article-title":"Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial","volume":"10","author":"Capdevila","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"2026092112474581200_dgag371-B104","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092112474581200_dgag371-B105","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026092112474581200_dgag371-B106","first-page":"46","article-title":"The first pediatric case of glucagon receptor defect due to biallelic mutations in GCGR is identified by newborn screening of elevated arginine","volume":"17","author":"Li","year":"2018","journal-title":"Mol Genet Metab Rep"},{"issue":"6","key":"2026092112474581200_dgag371-B107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ajhp\/zxaf324","article-title":"Glycerol phenylbutyrate","volume":"83","year":"2026","journal-title":"Am J Health Syst Pharm"},{"issue":"21","key":"2026092112474581200_dgag371-B108","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2303226","article-title":"Liver transplantation in a woman with mahvash disease","volume":"389","author":"Robbins","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2026092112474581200_dgag371-B109","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/bjs\/znab088","article-title":"Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA)","volume":"108","author":"Heidsma","year":"2021","journal-title":"Br J Surg"},{"issue":"12","key":"2026092112474581200_dgag371-B110","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/bjs\/znac267","article-title":"Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial","volume":"109","author":"Partelli","year":"2022","journal-title":"Br J Surg"},{"issue":"5","key":"2026092112474581200_dgag371-B111","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2265.2011.03967.x","article-title":"Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour","volume":"74","author":"Eldor","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10401","key":"2026092112474581200_dgag371-B112","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"10295","key":"2026092112474581200_dgag371-B113","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"10140","key":"2026092112474581200_dgag371-B114","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"2026092112474581200_dgag371-B115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2026092112474581200_dgag371-B116","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMoa2600751","article-title":"Survodutide once weekly for the treatment of adults with obesity","volume":"395","author":"le Roux","year":"2026","journal-title":"N Engl J Med"},{"issue":"8","key":"2026092112474581200_dgag371-B117","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S2213-8587(25)00092-0","article-title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","volume":"13","author":"Coskun","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026092112474581200_dgag371-B118","article-title":"Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event","volume":"2025","author":"Weschle","year":"2025","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag371\/70992678\/dgag371.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag371\/70992678\/dgag371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:48:07Z","timestamp":1790009287000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag371\/8787868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":118,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag371","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"dgag371"}}